|
28 May 2020 |
Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
|
|
28 May 2020 |
Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
|
|
28 May 2020 |
PureTech Advances LYT-100 (Deupirfenidone) for Treatment of Serious Respiratory Complications that Persist Following Resolution of COVID-19 Infection
|
|
27 May 2020 |
FDA Approves Only Drug in U.S. to Treat Severe Malaria
|
|
26 May 2020 |
DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH
|
|
26 May 2020 |
Monte Rosa Therapeutics Discloses $32.5 Million Financing
|
|
26 May 2020 |
Qurient Announces U.S. FDA Clearance of IND Application for Q702, a Novel Cancer Immunotherapy
|
|
26 May 2020 |
Novaremed Announces IND Submitted to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy; Also Announces the Appointment of Three New Board Members
|
|
25 May 2020 |
Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases
|
|
23 May 2020 |
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer
|
|
23 May 2020 |
ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
|
|
22 May 2020 |
Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
|
|
21 May 2020 |
Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease
|
|
21 May 2020 |
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)
|
|
21 May 2020 |
Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis
|
|
20 May 2020 |
Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
|
|
20 May 2020 |
Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies
|
|
20 May 2020 |
Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer
|
|
19 May 2020 |
MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3 - a Potential New Gold Standard, First-line Treatment for Clostridium difficile Infection (CDI)
|
|
19 May 2020 |
Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454
|
|
19 May 2020 |
Adjuvance Technologies Announces NIH Funding for COVID-19 Vaccine Research
|
|
18 May 2020 |
Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain
|
|
18 May 2020 |
Oculis Reports Positive Top-line Data From SKYGGN (Phase 2) Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery
|
|
18 May 2020 |
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
|
|
18 May 2020 |
VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
|
